Spyre Therapeutics entered into an underwriting agreement to sell an aggregate of 4,117,648 shares of common stock, with an option for an additional 617,647 shares. The offering will be led by Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated, facilitating capital raising for the company.